MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction
暂无分享,去创建一个
[1] L. Tavazzi,et al. GISSI-2: mortality plus extensive left-ventricular damage as "end-point" , 1990, The Lancet.
[2] J. Hsia,et al. Heparin versus aspirin after recombinant tissue plasminogen activator therapy in myocardial infarction: A randomized trial , 1990 .
[3] P. Marino,et al. Effect of streptokinase on left ventricular modeling and function after myocardial infarction: the GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico) Trial. , 1989, Journal of the American College of Cardiology.
[4] B. Sobel. Coronary thrombolysis and the new biology. , 1989, Journal of the American College of Cardiology.
[5] R. Califf,et al. Tissue plasminogen activator: why the backlash? , 1989, Journal of the American College of Cardiology.
[6] H. White,et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. , 1989, The New England journal of medicine.
[7] E. Rapaport. Thrombolytic agents in acute myocardial infarction. , 1989, The New England journal of medicine.
[8] E. Braunwald,et al. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? , 1989, Circulation.
[9] K. Lee,et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.
[10] B. Magnani,et al. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. , 1989, Journal of the American College of Cardiology.
[11] F. Van de Werf,et al. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.
[12] J. Wittes,et al. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. , 1988, JAMA.
[13] A. M. Skene,et al. TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.
[14] Dwight E. Peake,et al. Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .
[15] Sol Sherry,et al. Thrombolytic Therapy: Current Status , 1988 .
[16] F. Harrell,et al. Prognostic value of the simplified Selvester QRS score in patients with coronary artery disease. , 1988, Journal of the American College of Cardiology.
[17] E. Topol. Advances in Thrombolytic Therapy for Acute Myocardial Infarction , 1987, Journal of clinical pharmacology.
[18] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.
[19] Dwight Lemon,et al. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 , 1987 .
[20] S. Sherry. Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction? , 1987, The American journal of cardiology.
[21] F H Sheehan,et al. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. , 1987, Circulation.
[22] Harold T. Dodge,et al. Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .
[23] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.
[24] C. G. Blomqvist,et al. Identification and treatment of low-risk patients after acute myocardial infarction and coronary-artery bypass graft surgery. , 1986, New England Journal of Medicine.
[25] G S Wagner,et al. The Selvester QRS scoring system for estimating myocardial infarct size. The development and application of the system. , 1985, Archives of internal medicine.
[26] J. Fleiss,et al. Statistical methods for rates and proportions , 1973 .